BPC-157 upregulates VEGF, the vascular endothelial growth factor that directs the formation of new capillaries
7583% achieved 15% 26% of participants on 12 mg achieved 30% weight reduction Cardiometabolic Parameters Improvements in blood pressure, HbA1c, fasting glucose, insulin, LDL-cholesterol 72% of patients with prediabetes achieved normoglycemia Safety Most common adverse events: gastrointestinal (nausea, diarrhea, constipation) , dose-dependent, predominantly mild to moderate Heart rate: slight increase up to week 24, then decrease No severe hypoglycemia, medullary carcinoma, or C-cell hyperplasia Conclusions Retatrutide induced significant, dose-dependent weight reduction of up to 24.2% over 48 weeks
In research models, it has demonstrated enhancements in wound healing by up to 50% faster rates and modulation of gene expression related to tissue remodeling
Important Notes Practical points that keep daily administration of the blend safe and consistent
Still, we should be careful